These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1423323)

  • 1. T cell immune response to cancer in humans and its relevance for immunodiagnosis and therapy.
    Oliver RT; Nouri AM
    Cancer Surv; 1992; 13():173-204. PubMed ID: 1423323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons from T cell responses to virus induced tumours for cancer eradication in general.
    Melief CJ; Kast WM
    Cancer Surv; 1992; 13():81-99. PubMed ID: 1423326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy.
    Bukowski RM; Rayman P; Uzzo R; Bloom T; Sandstrom K; Peereboom D; Olencki T; Budd GT; McLain D; Elson P; Novick A; Finke JH
    Clin Cancer Res; 1998 Oct; 4(10):2337-47. PubMed ID: 9796963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [MHC tetramers: tracking specific immunity].
    Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
    Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunotherapy of cancer].
    Andersen MH; Schmidt H; Gehl J; von der Maase H; Straten P
    Ugeskr Laeger; 2002 Jun; 164(23):3008-16. PubMed ID: 12082849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune monitoring of cancer patients undergoing experimental immunotherapy.
    Shankar G; Salgaller ML
    Curr Opin Mol Ther; 2000 Feb; 2(1):66-73. PubMed ID: 11249653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
    Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
    Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
    Kim CJ; Parkinson DR; Marincola F
    J Immunother; 1998 Jan; 21(1):1-16. PubMed ID: 9456431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
    Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
    Mikysková R; Bubeník J; Vonka V; Smahel M; Indrova M; Bieblová J; Símová J; Jandlová T
    Int J Oncol; 2005 Feb; 26(2):521-7. PubMed ID: 15645139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma.
    Stopeck AT; Gessner A; Miller TP; Hersh EM; Johnson CS; Cui H; Frutiger Y; Grogan TM
    Clin Cancer Res; 2000 Oct; 6(10):3904-9. PubMed ID: 11051236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Boosting the immune response: an alternative combination therapy for cancer patients.
    Thyphronitis G; Koutsilieris M
    Anticancer Res; 2004; 24(4):2443-53. PubMed ID: 15330197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer.
    Lefebvre S; Antoine M; Uzan S; McMaster M; Dausset J; Carosella ED; Paul P
    J Pathol; 2002 Mar; 196(3):266-74. PubMed ID: 11857488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific and non-specific responses in host resistance to tumors.
    Baldwin RW
    Tokai J Exp Clin Med; 1983 Dec; 8(5-6):419-28. PubMed ID: 6398929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour immunotherapy: the adjuvant treatment of the 21st century?
    Bremers AJ; Kuppen PJ; Parmiani G
    Eur J Surg Oncol; 2000 Jun; 26(4):418-24. PubMed ID: 10873365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B; Navabi H; Adams M
    Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient recovery of HLA class I expression in human tumor cells after beta2-microglobulin gene transfer using adenoviral vector: implications for cancer immunotherapy.
    del Campo AB; Aptsiauri N; Méndez R; Zinchenko S; Vales A; Paschen A; Ward S; Ruiz-Cabello F; González-Aseguinolaza G; Garrido F
    Scand J Immunol; 2009 Aug; 70(2):125-35. PubMed ID: 19630918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.